€24.86
5.40%
Paris, Oct 08, 05:35 pm CEST. Closed.
Why the stock moved Why the stock moved Beta
ISIN
FR0004065605
Symbol
MEDCL

Medincell Target price 2026 - Analyst rating & recommendation

Medincell Classifications & Recommendation

Buy
94%
Hold
6%

Medincell Price Target

Target Price €34.68
Price €24.86
Potential
Number of Estimates 12
12 Analysts have issued a price target Medincell 2027 . The average Medincell target price is €34.68. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 16 Analysts recommend Medincell to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medincell stock has an average upside potential 2027 of . Most analysts recommend the Medincell stock at Purchase.

Sales and Margin forecast 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Mar '26 2027
Estimates
Revenue Million € 19.52 49.15
23.21% 151.78%
Net Margin -160.30% 66.59%
120.97% 141.54%

10 Analysts have issued a sales forecast Medincell 2027 . The average Medincell sales estimate is

€49.1m
unlock
. This is
73.00% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€75.6m 166.10%
unlock
, the lowest is
€38.1m 34.19%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 €19.5m 23.21%
2027
€49.1m 151.78%
unlock
2028
€79.0m 60.64%
unlock
2029
€108m 36.36%
unlock
2030
€126m 17.41%
unlock
2031
€139m 9.98%
unlock
2032
€166m 19.47%
unlock
2033
€270m 62.41%
unlock

8 Analysts have issued an Medincell EBITDA forecast 2027. The average Medincell EBITDA estimate is

€8.5m
unlock
. This is
209.28% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€32.6m 518.92%
unlock
, the lowest is
€-8.0m 2.50%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2028
€58.7m 591.44%
unlock
2029
€68.3m 16.33%
unlock

EBITDA Margin

2028
74.36% 330.32%
unlock
2029
63.44% 14.69%
unlock

9 Medincell Analysts have issued a net profit forecast 2027. The average Medincell net profit estimate is

€32.7m
unlock
. This is
264.06% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€38.2m 291.63%
unlock
, the lowest is
€26.6m 233.33%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 €-31.3m 69.69%
2027
€32.7m 204.60%
unlock
2028
€30.7m 6.26%
unlock
2029
€55.1m 79.47%
unlock
2030
€71.7m 30.13%
unlock
2031
€89.9m 25.42%
unlock
2032
€134m 48.83%
unlock
2033
€274m 105.24%
unlock

Net Margin

2026 -160.30% 120.97%
2027
66.59% 141.54%
unlock
2028
38.86% 41.64%
unlock
2029
51.14% 31.60%
unlock
2030
56.68% 10.83%
unlock
2031
64.64% 14.04%
unlock
2032
80.53% 24.58%
unlock
2033
101.77% 26.38%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Mar '26 2027
Estimates
Earnings Per Share € -0.95 0.99
53.23% 204.21%
P/E 26.58
EV/Sales 19.65

9 Analysts have issued a Medincell forecast for earnings per share. The average Medincell EPS is

€0.99
unlock
. This is
262.30% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
€1.16 290.16%
unlock
, the lowest is
€0.80 231.15%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 €-0.95 53.23%
2027
€0.99 204.21%
unlock
2028
€0.93 6.06%
unlock
2029
€1.66 78.49%
unlock
2030
€2.16 30.12%
unlock
2031
€2.71 25.46%
unlock
2032
€4.04 49.08%
unlock
2033
€8.29 105.20%
unlock

P/E ratio

Current -43.08 1.13%
2027
26.58 161.70%
unlock
2028
28.35 6.66%
unlock
2029
15.80 44.27%
unlock
2030
12.14 23.16%
unlock
2031
9.68 20.26%
unlock
2032
6.50 32.85%
unlock
2033
3.17 51.23%
unlock

Based on analysts' sales estimates for 2027, the Medincell stock is valued at an EV/Sales of

19.65
unlock
and an P/S ratio of
19.56
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 34.00
2027
19.65 42.19%
unlock
2028
12.24 37.75%
unlock
2029
8.97 26.67%
unlock
2030
7.64 14.83%
unlock
2031
6.95 9.07%
unlock
2032
5.82 16.29%
unlock
2033
3.58 38.43%
unlock

P/S ratio

Current
2027
19.56 42.20%
unlock
2028
12.18 37.75%
unlock
2029
8.93 26.67%
unlock
2030
7.60 14.83%
unlock
2031
6.91 9.07%
unlock
2032
5.79 16.29%
unlock
2033
3.56 38.43%
unlock

Current Medincell Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JEFFERIES
Locked
➜
Locked
Locked Sep 23 2026
ODDO BHF
Locked
➜
Locked
Locked Sep 08 2026
TP ICAP
Locked
➜
Locked
Locked Jul 30 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jul 30 2026
PORTZAMPARC BNP PARIBAS
Locked
➜
Locked
Locked Jul 30 2026
PORTZAMPARC BNP PARIBAS
Locked
➜
Locked
Locked Jun 29 2026
PORTZAMPARC BNP PARIBAS
Locked
➜
Locked
Locked Jun 28 2026
Analyst Rating Date
Locked
JEFFERIES:
Locked
➜
Locked
Sep 23 2026
Locked
ODDO BHF:
Locked
➜
Locked
Sep 08 2026
Locked
TP ICAP:
Locked
➜
Locked
Jul 30 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jul 30 2026
Locked
PORTZAMPARC BNP PARIBAS:
Locked
➜
Locked
Jul 30 2026
Locked
PORTZAMPARC BNP PARIBAS:
Locked
➜
Locked
Jun 29 2026
Locked
PORTZAMPARC BNP PARIBAS:
Locked
➜
Locked
Jun 28 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today